Kedudukan dalam Saham
#40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Harga Saham
$0.01292666
Disegerakkan terakhir: 2025-04-08
Perubahan (1 tahun)
0.00%
Perdagangan Synairgen plc (SNG)
Harga SNG dengan permodalan pasaran b
Modal pasaran bagi Synairgen plc(SNG)
Modal Pasaran: $157.54K
Sehingga August 2026, Synairgen plc mempunyai modal pasaran sebanyak $157.54K. Ini menjadikan Synairgen plc syarikat ke-40400th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Synairgen plc dari 2004 hingga 2026
SNG berbanding dengan 5 teratas yang paling popular stocks
| Harga SNG |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.470T
|
+3,471,815,955.71%
|
|
|
|
|
$4.467T
|
+2,835,495,357.75%
|
|
|
|
|
$4.174T
|
+2,649,712,215.36%
|
|
|
|
|
$3.700T
|
+2,348,642,204.32%
|
|
|
|
|
$2.854T
|
+1,811,807,993.27%
|
